DEA telehealth rules, explained

The rule today

Until the end of December 31, 2026, a DEA-registered clinician may prescribe Schedule II–V controlled substances by telemedicine without first seeing the patient in person. Most ADHD stimulants are Schedule II. The conditions: the prescription must serve a legitimate medical purpose, the visit must use an interactive telecommunications system, and the clinician must hold the right DEA registration.

Source: 42 CFR 12.1 (eCFR); Fourth Temporary Extension, Federal Register, Dec 31, 2025

The proposed permanent rule

On January 17, 2025, the DEA proposed "Special Registrations for Telemedicine." Under the proposal:

• Schedule II medications, which include most stimulants, would require an Advanced Telemedicine Prescribing Registration, limited to certain board-certified specialties such as psychiatry and pediatrics.
• Clinicians would need a state telemedicine registration for each state where their patients are located.
• The DEA asked for comment on whether prescriber and patient must be in the same state, and on limiting telemedicine to under 50% of a clinician's monthly Schedule II prescriptions.

These are proposals. The final rule may differ.

Sources: Federal Register NPRM, Jan 17, 2025; DEA press release, Jan 16, 2025

Where things stand UNCONFIRMED

A secondary source reports that a final rule (RIN 1117-AB40) reached White House review on August 25, 2026, with final action targeted for November 2026. The text is not public. We have not confirmed this against an official government source yet.

Source: MDside (secondary)

What to watch

• Whether a final rule is published before January 1, 2027, or whether the deadline is extended again.
• State laws still decide who may prescribe Schedule II medications, such as nurse practitioners in some states.
• If you take a stimulant prescribed by telehealth, ask your own clinic how it plans to handle the change.